A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers

Full Title

Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN 0903/AMC-080)


Allogeneic stem cell transplantation involves the donation of stem cells from a donor to a patient to help the patient’s body build a healthy blood-forming system. It is commonly used to treat patients with hematologic cancers (such as lymphoma, leukemia, and myelodysplastic syndromes) that have returned or continue to grow despite chemotherapy and other treatments.

Allogeneic stem cell transplantation carries with it a risk of infection, and therefore has not been well-studied in patients with HIV. The purpose of this study is to evaluate the safety and effectiveness of allogeneic bone marrow transplantation in HIV-infected patients with hematologic cancers that cannot be cured with chemotherapy.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be infected with HIV and have acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin or non-Hodgkin lymphoma, or a myelodysplastic syndrome that cannot be cured with chemotherapy.
  • Patients must have a matched stem cell donor.
  • Patients must continue to take their antiretroviral therapy during the study.
  • Patients must be age 15 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Craig Sauter at 212-639-3460.